Biohaven Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.02.22	BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS (PR Newswire)
24.02.22	Ausblick: Biohaven Pharmaceutical legt Zahlen zum jüngsten Quartal vor (finanzen.net)
16.02.22	BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022 (PR Newswire)
14.02.22	Biohaven Pharma: Rimegepant Asia-Pacific Phase 3 Study Meets Co-primary Endpoints (RTTNews)
06.01.22	BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY (PR Newswire)
05.01.22	Biohaven, Pfizer Announce Successful Closing Of Collaboration Agreements - Quick Facts (RTTNews)
06.12.21	Biohaven Names Matthew Buten CFO; To File NDA For Zavegepant In 1Q22 Based On Phase 3 Trial Results (RTTNews)
17.11.21	Biohaven Reports Approval Of NURTEC ODT In Kuwait For Acute Treatment Of Migraine (RTTNews)
09.11.21	Pfizer Inks Deal With Biohaven To Commercialize Rimegepant, Zavegepant, Outside The U.S. (RTTNews)
09.11.21	Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States (PR Newswire)
09.11.21	Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments (PR Newswire)
08.11.21	Ausblick: Biohaven Pharmaceutical präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
04.11.21	Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021 (PR Newswire)
05.10.21	Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment (PR Newswire)
27.09.21	Biohaven's Verdiperstat Fails To Show Efficacy For Multiple System Atrophy Treatment; Stock Down (RTTNews)
09.08.21	Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments (PR Newswire)
07.08.21	Ausblick: Biohaven Pharmaceutical mit Zahlen zum abgelaufenen Quartal (finanzen.net)
29.07.21	Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race (PR Newswire)
28.07.21	Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202 (PR Newswire)
07.07.21	Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment (PR Newswire)
23.06.21	Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven (PR Newswire)
17.06.21	Biohaven Appoints Kishen Mehta to Board of Directors (PR Newswire)
01.06.21	So schätzen die Analysten die Zukunft der Biohaven Pharmaceutical-Aktie ein (finanzen.net)
08.05.21	Ausblick: Biohaven Pharmaceutical öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
30.04.21	Biohaven Pharmaceutical-Aktie: Experten empfehlen Biohaven Pharmaceutical im April mehrheitlich zum Kauf (finanzen.net)
27.03.21	Biotech Stocks Facing FDA Decision In April 2021 (RTTNews)
20.01.21	ACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimer's Trial, GRTS Joins COVID-19 Vaccine Race (RTTNews)
31.12.20	Analysten sehen bei Biohaven Pharmaceutical-Aktie Potenzial (finanzen.net)
10.09.20	Biohaven Pharma Advances Oral Formulations Of Zavegepant Into Human Studies (RTTNews)
07.08.20	Stock Alert: Biohaven Pharma Shares Up 8% (RTTNews)
22.07.20	AUPH Faces FDA In Jan, ARCT To Advance LUNAR-COV19 Vaccine, IFRX On Watch, All Eyes On ALEC (RTTNews)
31.05.20	Analysten sehen für Biohaven Pharmaceutical-Aktie Luft nach oben (finanzen.net)
30.04.20	So schätzen die Analysten die Biohaven Pharmaceutical-Aktie im April 2020 ein (finanzen.net)
09.04.20	Biohaven Pharma To Begin Phase 2 Trial Of Intranasal Vazegepant (RTTNews)
31.03.20	Analysten sehen für Biohaven Pharmaceutical-Aktie Luft nach oben (finanzen.net)
31.03.20	AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)
30.03.20	Stock Alert: Biohaven Pharmaceutical Down 7% (RTTNews)
28.02.20	FDA Nod For BHVN's Drug, IBIO On Watch, SGMO Soars On Biogen Deal (RTTNews)
23.02.20	Biohaven Pharma (BHVN) Has A Pair Of Important Catalysts In Q1 (RTTNews)
11.02.20	ACST Plunges On Data Delay, MREO On Watch, AQST Faces FDA In Sep. (RTTNews)
10.02.20	Stock Alert: Biohaven Down 8% After Anxiety Drug Fails Late-stage Study (RTTNews)
22.11.19	Did This Stock Catch Your Eye? (BHVN) (RTTNews)
22.07.19	FDA Says No To BHVN, Detraxi Eyeing Solution For Blood Shortage, MRKR On Watch (RTTNews)
07.06.19	Pain, Pain Go Away - The Suicide Disease Drug Pipeline (RTTNews)
09.03.19	Did You Invest In These Biotech Stocks? (RTTNews)
23.01.19	Biohaven Gets FDA May Proceed Letter For Phase 3 Trial Of BHV-3241 For MSA (RTTNews)
04.12.18	GBT On Fast Track, GH In Good Health, For BHVN, It's All Gain, No Pain (RTTNews)
15.08.18	Keep An Eye On ATNM Today, PETQ Upbeat, MTFB To Face FDA In Feb (RTTNews)
19.06.18	CSBR Up 36% This Month, ZIOP Hit By Clinical Hold, Watch Out For SRPT Today (RTTNews)
19.06.18	Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	97.61	0.60 %	K V
Swisscom	510.00	0.59 %	K V
Swiss Re	145.20	0.52 %	K V
Swiss Life Hldg	785.20	0.00 %	K V
Sonova Hldg	292.00	-0.03 %	K V
Sika	227.40	-1.56 %	K V
Part Grp Hldg	1’318.00	-1.72 %	K V
Alcon	83.00	-1.80 %	K V
UBS Group	30.09	-2.05 %	K V
Kuehne+Nagel Int	206.90	-4.52 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten